Influence of dual antiplatelet therapy on mean platelet volume in patients with coronary artery disease undergoing percutaneous coronary intervention

详细信息    查看全文

• 作者：Tadanao Higaki ; Satoshi Kurisu ; Noriaki Watanabe ; Hiroki Ikenaga…
• 关键词：Mean platelet volume ; Dual antiplatelet therapy ; Coronary artery disease
• 刊名：Heart and Vessels
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：31
• 期：3
• 页码：269-274
• 全文大小：519 KB
• 参考文献：1.Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533CrossRef PubMed
  2.Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420CrossRef PubMed
  3.Anzai A, Maekawa Y, Kodaira M, Mogi S, Arai T, Kawakami T, Kanazawa H, Hayashida K, Yuasa S, Kawamura A, Fukuda K (2014) Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians. Heart Vessels. doi:10.​1007/​s00380-014-0474-y
  4.Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M (2010) Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 56:1447–1455CrossRef PubMed
  5.Cameron HA, Phillips R, Ibbotson RM, Carson PH (1983) Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 287:449–451CrossRef
  6.Yarlioglues M, Kaya MG, Ardic I, Dogdu O, Kasapkara HA, Gunturk E, Akpek M, Kalay N, Dogan A, Ozdogru I, Oguzhan A (2011) Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients. Blood Press 20:92–97CrossRef PubMed
  7.Pizzulli L, Yang A, Martin JF, Luderitz B (1998) Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart 19:80–84CrossRef
  8.Vizioli L, Muscari S, Muscari A (2009) The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 63:1509–1515CrossRef PubMed
  9.Shah B, Oberweis B, Tummala L, Amoroso NS, Lobach I, Sedlis SP, Grossi E, Berger JS (2013) Mean platelet volume and long-term mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 111:185–189CrossRef PubMed PubMedCentral
  10.Sun X, Jia Z (2012) A brief review of biomarkers for preventing and treating cardiovascular diseases. J Cardiovasc Dis Res 3:251–254CrossRef PubMed PubMedCentral
  11.De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell’Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P (2009) Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 206:292–297CrossRef PubMed
  12.Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117:399–404CrossRef PubMed
  13.Kario K, Matsuo T, Nakao K (1992) Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 14:281–287CrossRef PubMed
  14.Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, Lakasas G (2004) Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 15:475–478CrossRef PubMed
  15.Coban E, Ozdogan M, Yazicioglu G, Akcit F (2005) The mean platelet volume in patients with obesity. Int J Clin Pract 59:981–982CrossRef PubMed
  16.Pathansali R, Smith N, Bath P (2001) Altered megakaryocyte-platelet haemostatic axis in hypercholesterolaemia. Platelets 12:292–297CrossRef PubMed
  17.Savi P, Herbert JM (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:174–183CrossRef PubMed
  18.Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323CrossRef PubMed
  19.Erhart S, Beer JH, Reinhart WH (1999) Influence of aspirin on platelet count and volume in humans. Acta Haematol 101:140–144CrossRef PubMed
  20.Colkesen Y, Coskun I, Muderrisoglu H (2013) The effect of aspirin on mean platelet volume in patients with paroxysmal atrial fibrillation. Platelets 24:263–266CrossRef PubMed
  21.Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI (2008) Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 52:743–749CrossRef PubMed
  22.De Luca G, Secco GG, Iorio S, Verdoia M, Bellomo G, Marino P (2012) Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study. Blood Coagul Fibrinolysis 23:756–759CrossRef PubMed
  23.Le Breton H, Plow EF, Topol EJ (1996) Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 28:1643–1651CrossRef PubMed
  24.Yang A, Pizzulli L, Luderitz B (2006) Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 117:371–377CrossRef PubMed
  25.Avci A, Boyaci A, Cagli K, Cosgun A, Gokce V, Duru E, Korkmaz S (2004) Influence of haematological parameters before coronary angioplasty on subsequent restenosis. Acta Cardiol 59:263–268CrossRef PubMed
  26.Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156CrossRef PubMed PubMedCentral
  27.Kaiser C, Galatius S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M, BASKET–PROVE Study Group (2010) Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 363:2310–2319CrossRef PubMed
  28.Lunder M, Ziberna L, Janić M, Jerin A, Skitek M, Sabovič M, Drevenšek G (2013) Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels 28:246–254CrossRef PubMed
  29.Kaneko H, Yajima J, Oikawa Y, Tanaka S, Fukamachi D, Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Kano H, Uejima T, Koike A, Nagashima K, Kirigaya H, Sawada H, Aizawa T, Yamashita T (2014) Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 29:21–28CrossRef PubMed PubMedCentral
  30.Sivri N, Tekin G, Yalta K, Aksoy Y, Senen K, Yetkin E (2013) Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol 10:1042–1047CrossRef
  
• 作者单位：Tadanao Higaki (1)
  Satoshi Kurisu (1)
  Noriaki Watanabe (1)
  Hiroki Ikenaga (1)
  Takashi Shimonaga (1)
  Toshitaka Iwasaki (1)
  Naoya Mitsuba (1)
  Ken Ishibashi (1)
  Yoshihiro Dohi (1)
  Yukihiro Fukuda (1)
  Yasuki Kihara (1)
  
  1. Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima, 734-8551, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Cardiac Surgery
  Vascular Surgery
  Biomedical Engineering
  Interventional Radiology
  Ultrasound
  
• 出版者：Springer Japan
• ISSN：1615-2573

文摘

Mean platelet volume (MPV) is a well-established marker of platelet activation, and recent studies have shown that platelet activation is central to the processes in the pathophysiology of coronary artery disease (CAD). The study population consisted of 45 patients with stable CAD who underwent successful percutaneous coronary intervention (PCI) with drug-eluting stents. We selected 45 age- and sex-matched control subjects without cardiovascular diseases who did not require antiplatelet therapy. Hematological test was performed 3 times within 1 month before DAPT (baseline), at 2 weeks after PCI (post PCI) and at 9 months after PCI (follow-up). Compared to control subjects, MPV was significantly larger in patients with CAD (10.0 ± 0.6 vs 10.7 ± 0.8 fl, p < 0.01) although there was no significant difference in white blood cell count, hemoglobin, and platelet count between the 2 groups. In patients with CAD, DAPT did not affect platelet count (19.3 ± 4.8 × 104–18.9 ± 4.6 × 104/μl) or MPV (10.7 ± 0.8–10.5 ± 0.9 fl) during the follow-up period. MPV remained to be higher at follow-up in patients with CAD despite DAPT compared to control subjects (10.1 ± 0.7 vs 10.5 ± 0.9 fl, p < 0.05). Our data suggested that MPV might not be suitable for monitoring the effects of DAPT on platelet activity in patients with CAD undergoing PCI.